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AbstrACt
Introduction Evidence suggests bowel scope screening 
(BSS) can significantly reduce an individual’s risk of 
developing colorectal cancer (CRC). BSS for 55 year olds 
was therefore introduced to the English Bowel Cancer 
Screening Programme (BCSP) in 2013. However, the 
benefits are only gained from test completion and uptake 
is low (43%). Primary care involvement has consistently 
shown benefits to cancer screening uptake and so this 
study aims to build on this knowledge and evaluate 
general practitioner (GP) practice led interventions 
designed to increase BSS attendance.
Methods and analysis A three-arm randomised controlled 
trial will be conducted to evaluate three interventions: one 
intervention for prospective BSS invitees (primer letter 
with locally tailored leaflet sent by an individual’s GP 
practice) and two interventions for those who do not attend 
their BSS appointment (a self-referral letter sent by an 
individual’s GP practice and a patient navigation call made 
on behalf of an individual’s GP practice). The trial will be 
set in Yorkshire. Individuals soon to receive their invitation 
to attend BSS at one of the Hull and East Yorkshire Bowel 
Cancer Screening centre sites, will be randomly assigned 
to one of three groups: control (usual care; no input from 
GP practice), Intervention group A (primer letter/leaflet and 
a self-referral letter), Intervention group B (primer letter/
leaflet and a patient navigation call). Attendance data will 
be obtained from the BCSP database (via National Health 
Service (NHS) Digital) 3 months after the last intervention. 
Regression analysis will compare uptake, and additional 
clinical outcomes, across the three groups. The analysis will 
be multivariate and adjust for several covariates including 
gender and area-level deprivation.
Ethics and dissemination NHS ethical approval has been 
obtained from London-Harrow Research Ethics Committee. 
The results will be submitted for publication in a peer-
reviewed journal and presented at conferences.
trial registration number ISRCTN16252122; Pre-results.
IntroduCtIon 
Bowel cancer (colorectal cancer, CRC) is the 
second leading cause of cancer-related deaths 
in the UK.1 However, screening opportunities 
to help reduce mortality from CRC via early 
detection or prevention are available.
Since 2006 the National Health Service 
(NHS) has invited all men and women, aged 
60–69 (now increased to 74), to complete 
a home-based guaiac faecal occult blood 
test (gFOBt) every 2 years with the aim of 
detecting CRC in its early stages, when it is 
considered more treatable. More recently 
(from 2013), the English Bowel Cancer 
Screening Programme (BCSP) has intro-
duced bowel scope screening (BSS) as an 
additional test to help reduce an individual’s 
risk of getting CRC.
Preceding the introduction of BSS, a UK 
trial of the test with a 10-year follow-up, 
found BSS to reduce CRC incidence in those 
who were screened by 33% and mortality 
by 43%.2 Evidence of BSS maintaining its 
protective value for 17 years has recently been 
published.3
strengths and limitations of this study
 ► This trial builds on previous work indicating a posi-
tive impact of similar interventions.
 ► This trial follows on from a Yorkshire-based cancer 
report that interventions delivered through primary 
care are most effective at increasing uptake.
 ► While each intervention is delivered through primary 
care, the study is designed to have minimal influ-
ence on the workload of each practice.
 ► The study is limited to one region in England po-
tentially limiting the generalisability of our findings.
 ► Hull and East Yorkshire Bowel Cancer Screening 
centre currently only has two sites offering bowel 
scope screening, limiting the number of general 
practices that are eligible to take part in this study.
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bss and the invitation process
BSS involves having a one-off flexible sigmoidoscopy to 
find and remove polyps within the lower part of the 
large bowel (rectum and sigmoid colon), before they 
can become cancerous. Individuals registered with a 
general practice in England, will become eligible for 
BSS at the age of 55 and 2 months. A preinvitation 
letter introducing a forthcoming appointment letter is 
first sent to eligible individuals along with an 11-page 
information booklet. The appointment letter is then 
sent 2 weeks later and includes a specified appointment 
date and time (set 6 weeks in advance), which individ-
uals are asked to confirm by either a phone call or the 
return of a reply slip. If no confirmation is received 
by the screening centre, an appointment reminder 
letter is sent, followed 2 weeks later by a cancellation 
later if still no confirmation is received in that time 
period. If confirmation is received, a consent form and 
enema kit is sent out approximately 1–2 weeks before 
the appointment. For those who do not attend their 
confirmed appointment, a letter to confirm cancella-
tion of the BSS appointment is sent. No more contact 
is made with the individual until they are eligible for a 
different bowel cancer screening test (ie, gFOBt) at age 
60 (see figure 1). However, the individual can make a 
self-referral and initiate a new appointment process up 
until this point.
uptake of bss
Despite the benefits of BSS, uptake of the test is low 
(43%).4 Similar to gFOBt, uptake of BSS is socially graded 
with those living in more deprived areas less likely to take 
part.4 5 In contrast to gFOBt participation, males are 
significantly more likely than females to attend (45% vs 
42%).4 Interventions to enhance uptake and minimise 
inequalities as BSS continues to be rolled out across 
England are warranted.
Yorkshire and the Humber was one of the last regions 
in England to begin the BSS roll-out. Hull is a particularly 
deprived area within the region and has been identified as 
having one of the highest numbers of preventable cancer 
deaths in England (117.9 per 100 000 compared with the 
English average of 79.4 per 100 000).6 A high uptake of 
BSS could play a vital role in reducing the number of 
preventable cancer deaths and, as such, Hull was selected 
as the principal study setting.
developed interventions
The interventions designed for this study have evolved 
from previous literature and are to be delivered 
external to the current programme structure. In a 
review of cancer screening participation interventions, 
general practitioner (GP) endorsement was found to 
have a reliably positive influence on uptake.7 However, 
the level of endorsement needed for the most positive 
effect is unclear. Within CRC screening, various degrees 
of positive outcomes have been documented using 
personalised letters signed by an individual’s GP,8 and 
a simple statement to acknowledge GP practice support 
of the screening programme in another (ASCEND).5
Within this study, we have opted to enhance the role of 
primary care endorsement within the screening context 
and have designed a letter, to be sent by an individual’s 
GP practice ahead of the NHS invitation, to introduce 
BSS to patients and prime them for the NHS BCSP invi-
tation process. This letter additionally builds on the liter-
ature to suggest a role for prescreening interventions.7 9 
A further letter sent to non-attenders to remind them of 
the benefits of the test and the option to self-refer will 
also be included in this study. This intervention addition-
ally draws on the literature suggesting a positive impact of 
personalised reminders on uptake.7
A more generic GP endorsement is also included in a 
leaflet designed as a brief introduction to BSS, with local 
tailoring to further invoke personalisation. Such a leaflet 
has been found to enhance BSS participation, over and 
above the standard NHS BSS information booklet, when 
included with a self-referral reminder sent 12 and 24 
months after the original invitation.10
A further intervention included in this study is a 
patient navigation (PN) call to BSS non-attenders from 
the individual’s GP practice. PN was founded within the 
USA and was introduced to help minority groups iden-
tify and overcome barriers to access appropriate cancer 
care, and thereby lower socioeconomic health inequal-
ities.11 PN offers one-to-one support to individuals/
patients and has been applied to CRC screening in the 
USA with positive outcomes (eg, refs 12–14). A recent 
study tested the feasibility of PN to increase BSS uptake 
in England.15 Unfortunately, the process of asking 
prospective invitees for their telephone numbers at the 
start of the screening episode did not prove to be viable 
and did not allow the predicted value of PN to be eval-
uated.16 This study has been designed to try and over-
come this limitation by embedding PN within primary 
care where patient numbers are readily available and 
calls can be initiated by a familiar healthcare provider. 
Based on evidence demonstrating the value of PN, and 
UK evidence to support the use of GP practice based 
telephone calls to promote bowel cancer screening (eg, 
ref 17), we hypothesise that this intervention will have 
the most influence on BSS uptake.
MEthods And AnAlysIs
design
A randomised controlled trial with three parallel arms 
will test the impact of three interventions on uptake 
of BSS: one intervention will be aimed at BSS invitees 
and two at BSS non-attenders. A randomisation ratio 
of 1:1:1 will be applied for two intervention groups to 
be compared against each other and a control group 
of usual care (ie, no planned input from primary care; 
standard NHS BCSP contact procedures only). This 
will allow the additive value of the interventions to be 
considered in the analysis. Each intervention group 
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will include the invitee intervention and one of two 
non-attender interventions (see figure 1). At the end 
of data collection, an intervention process evaluation 
will be conducted involving telephone interviews with 
a selection of patients from each of the intervention 
groups, and a survey with staff at participating GP prac-
tices. The study is considered to be a low risk to patients 
and so will be ‘centrally monitored’ by the sponsor; any 
adverse events recognised by the GP practices will be 
reported to the sponsor.
recruitment and setting
All general practices who are ‘live’ for BSS and linked 
to screening sites at Hull Royal Infirmary or Castle Hill 
Hospital (England, UK) will be invited to participate in 
this study; recruited practices will be listed on the trial 
Figure 1 CONSORT flow diagram of process and expected attendance outcomes. Adopted from McGregor et al.15 BSS, 
bowel scope screening; CONSORT, Consolidated Standards of Reporting Trials; GP, general practitioner; NHS, National Health 
Service.
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register (ISRCTN16252122). As per the English NHS 
BCSP’s structure, patients registered with a GP practice 
will become eligible for BSS at the age of 55 and 2 months. 
For this study, patients, who will become eligible for BSS 
in approximately 1-month time (ie, are currently aged 55 
and 1 month) and fit the study inclusion criteria, will be 
automatically randomised into this study. No consent for 
study participation will be obtained from patients; a legal 
basis to allow access to confidential patient data without 
consent has been agreed (letter received 1 May 2018; 
CAG reference: 18/CAG/0049). However, each partici-
pating practice will display research notification posters 
to alert patients to this research project and will provide 
information on how to opt-out if they do not wish to be 
involved (see online supplementary appendices I and II 
for notification poster and leaflet).
Inclusion criteria
For an individual to be eligible for inclusion in the study, 
they must:
 ► Be registered with a participating GP practice.
 ► Be aged 55 years and 1 month (specifically, between 
55 and 21 days and 55 years and 48 days) at the time 
they are enrolled in the study. By using this day-spe-
cific time frame for the monthly selection of people 
to be randomised into this study, we will ensure indi-
viduals assigned to one of the two intervention groups 
receive their primer letter at least 2 weeks before their 
formal NHS preinvitation letter.
Exclusion criteria
Individuals will not be eligible if:
 ► They do not meet the clinical eligibility criteria for 
BSS (ie, they have had their large bowel removed; 
they have a stoma bag to collect their stool; they 
are currently being treated for inflammatory bowel 
disease; they are awaiting heart surgery or have had 
heart surgery in the last 3 months, have heart or lung 
problems severely limiting physical abilities).
 ► They are registered on the general practice’s clinical 
system as being a type 2 objector/opt-out.
 ► They are known to be receiving palliative care.
 ► They have been diagnosed with cancer (of any type) 
in the past 12 months.
Further exclusion criteria will be applied by each partic-
ipating GP practice independently to ensure patients who 
would not normally be sent materials from the GP are not 
contacted. The reasons will be documented.
Interventions
The content of each intervention has been heavily influ-
enced by local community work involving local resi-
dents and GP practice staff, and input from experts in 
public health, psychology, social marketing and health 
communication.
Primer letter and leaflet: A one-page letter priming 
patients to the delivery of the NHS invitation to attend 
BSS will be sent from their GP practice (GP practice 
headed paper and practice signatory) approximately 
1 month before they are eligible for BSS. This letter will 
position the relevance of BSS for the individual by high-
lighting that their age is a risk factor for CRC and that 
the test can help prevent the second most common cause 
of cancer deaths. A threefold A5 leaflet entitled ‘Bowel 
scope screening: a brief introduction’ will be sent with the 
letter. The leaflet aims to engage patients with the topic 
of BSS without the pressure of a demand to make a deci-
sion about attendance, and content draws on theoretical 
models of behavioural change, for example, the Health 
Belief Model.18 The leaflet reiterates the seriousness of 
CRC and that age is a risk factor, irrespective of health 
status, provides key benefits and risks of the test, social 
norm information and quotes addressing known barriers 
(eg, anticipated pain) from BSS attendees, a GP recom-
mendation for BSS and a visual representation of the 
protective function of BSS.
Self-referral reminder letter: A personally addressed, 
one A4 page, self-referral reminder letter will be sent to 
the patient from their GP practice. The letter will be sent 
in response to the GP practice receiving a notification 
from the screening hub indicating that their patient’s 
appointment was cancelled (ie, they did not confirm or 
attend their BSS appointment). It will highlight the oppor-
tunity to self-refer up until the individual’s 60th birthday, 
but will recommend this is done sooner. In addition to 
providing the phone number to call to directly book a 
new appointment, a second A4 page will be a response 
slip to be completed and returned to the screening 
centre to request a call to arrange a new appointment. 
A Freepost return envelope will be provided. The slip 
will also encourage patients to consider and communi-
cate appointment preferences and requirements that 
may have previously been a barrier to attendance, for 
example, expected sex of endoscopist or physical limita-
tions, so that these can be addressed during the call.
PN phone call: A phone call to the patient will be made 
from a trained navigator on behalf of participating GP 
practices. As above, the call will be initiated in response 
to the GP practice receiving a notification of non-atten-
dance from the screening hub. The call will aim to elicit 
the individual’s barriers to BSS attendance, with sugges-
tions and support to overcome them. Efforts will be made 
to correct misunderstandings about the purpose of BSS 
and what the test involves to facilitate informed choice. 
Support to arrange a new appointment will be offered. 
If questions or concerns arise during the PN call that the 
navigator cannot answer, a Specialist Screening Practi-
tioner from the local screening centre will be consulted. 
The PN episode will begin approximately 1 week after the 
GP practice receives a copy of the hub cancellation letter 
and will include up to five call attempts on various days 
and times across a 2-week period. A letter from the GP 
practice will be sent to anyone who cannot be contacted 
to highlight to the patient that a call to discuss BSS was 
attempted and that they can self-refer if they still wish to 
attend.
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Procedure
A list of patients from each participating GP practice who 
will be age eligible for a BSS invitation in 1 month will 
be extracted from the GP clinical system on a monthly 
basis by a research nurse (RN). Patients meeting any of 
the exclusion criteria will be removed. The final list will 
be added to the practice-specific study database with an 
integrated pregenerated block randomisation list for 
study groups (provided by statistician). To minimise 
cross-over effects, the address of each patient entered 
into the database will be reviewed with those previously 
entered and individuals living at the same address will 
be assigned the same study group. The name, address 
and NHS number of each person assigned to one of the 
two intervention groups will be securely uploaded to an 
online mailing company by the RN working exclusively 
on this study. The mailing company will provide a secure 
process for the printing and delivery of all personalised 
letters. The ‘return to sender address’ will be the rele-
vant GP practice and received returns will be noted on 
the study database.
The RN will then monitor the receipt of letters from 
the screening hub to inform the practice of their patients’ 
attendance/cancellation, noting in the study database if 
patients randomised into the study have attended BSS 
or not. For those assigned to one of the intervention 
groups, who have not attended BSS, a self-referral inter-
vention will be activated. Intervention 2A will involve 
the RN uploading the name, address and NHS number 
of relevant patients to the online mailing company for 
the mail-out of the self-referral reminder letter. This 
will be sent approximately 1 week following receipt of 
the hub outcome letter. Intervention 2B will involve the 
RN finding relevant patients’ telephone numbers from 
the GP clinical database and beginning the PN episode. 
The first call will be made 1 week after receipt of the hub 
letter. If no telephone contact is made after five attempts, 
a shortened version of the self-referral letter (eg no reply 
slip option included) will be sent via the online mailing 
company.
Three months following the last intervention, the 
RN will prepare two copies of each GP practice data-
base. The first copy will include only the study ID and 
NHS numbers of all patients randomised into the study. 
This copy will be sent to NHS Digital who will use the 
NHS number to collate specified data from the bowel 
cancer screening system, for example, date of BSS atten-
dance. Once collated, the data will be securely sent to 
the research team through University College London's 
(UCL) data safe haven with NHS numbers removed; data 
will not contain identifiable information. The second 
copy of the study database will be sent to the research 
team via UCL data safe haven with all personal details 
removed, for example, name, address, etc. The research 
team will combine the data received from each GP prac-
tice and NHS Digital using study ID numbers, in prepa-
ration for analysis (see figure 2).
Process evaluation
Where possible, the lead research team will randomly 
select patients to receive an invitation to be interviewed. 
Patients from each of the two intervention groups will be 
purposively selected: attended BSS following receipt of 
the primer letter and leaflet (n=33); attended following a 
self-referral intervention (n=33); did not attend following 
a self-referral intervention (n=33). Further invites will 
be sent depending on initial response rate with the aim 
of conducting an equal number of interviews across the 
outcome possibilities. The aim is to conduct 20 inter-
views (10 in each intervention group). The study ID 
numbers of selected patients will be sent to the RN who 
will obtain the corresponding names and addresses from 
the relevant GP practice database and upload them to the 
mailing company for the delivery of interview invitations 
(containing a GP-signed cover letter, information sheet, 
consent form and Freepost return envelope). Those inter-
ested will be asked to return the included consent form to 
the UCL researchers directly and a date and time for the 
interview will then be arranged. Participating patients will 
be offered a £10 voucher, which the interviewer will send 
to the address provided at the end of the interview.
The RN will oversee the delivery of an email with an 
embedded information sheet and link to the online 
survey to all staff in each of the participating GP practices. 
Confirmation of consent to use the data provided will be 
requested at the start of the survey. Staff members will be 
offered a chance to enter a draw to win a £50 voucher. 
Surveys will be completed anonymously; a separate link 
will direct participants to the prize draw whereby names 
and addresses can be entered separately to the online 
survey. All personal details received by the UCL research 
team will be securely held in the UCL Data Safe Haven 
until the payments are complete.
sample size
The sample size (n=2000) was calculated using a stan-
dard test of difference for two proportions. As the study 
contains three trial groups, the calculation was repeated 
for each pairwise comparison covering a primary research 
question in the planned analysis. The calculation giving 
the largest sample size requirement to test for a difference 
between any two of the three study groups was accepted 
and used as the sample size requirement for all three trial 
arms. The study has been designed to test for at least an 
8% point difference in uptake between any two of the 
three study groups, with expected uptake values of 35%, 
46% and 54% in the usual care, primer and self-referral 
letter, and primer and PN groups, respectively (40% for 
primer letter and leaflet alone), at the two-sided 5% alpha 
level with a 20% margin for type II error.
To ensure we meet our target sample size, we need to 
recruit at least 35 GP practices ‘live’ for BSS and linked 
to the two screening centre sites in Hull. Recruitment 
initiatives will include incentives for early responders, 
presentations or stalls at primary care events, newsletter 
advertisements, targeted email notifications, practice 
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visits. The study is also supported by the National Institute 
for Health Research (NIHR) Clinical Research Network 
Yorkshire and the Humber.
outcomes measures
The primary outcome measure will be the proportion 
of people who have attended BSS by 12 weeks post last 
intervention, within each group. Additional, secondary 
outcome measures will include, sociodemographic 
factors (eg, gender, Index of Multiple Deprivation (IMD) 
score, ethnicity) response to initial NHS invitation (did 
not respond or confirm/did respond or confirm); dates 
each intervention sent/calls made, date of attended 
BSS appointment, outcome of test (normal/abnormal/
cancer detected), offer of a colonoscopy (yes/no), atten-
dance at colonoscopy (yes/no) and screening episode 
final clinical outcome (not suitable for BSS/normal/risk 
level/cancer).
Planned analysis
Univariable and multivariable binary logistic regression 
will be used to investigate the association between study 
groups and BSS attendance before and after adjusting for 
baseline characteristics (eg, sex, ethnicity, IMD quintile 
and response to the initial invitation). A subgroup anal-
ysis will consider whether the time interval between the 
primer letter and NHS invitation has an effect on uptake.
Further regression analyses will assess whether the inter-
ventions are predictors of attendance at colonoscopy for 
those offered a follow-up examination in response to their 
BSS appointment. The clinical outcomes for individuals 
randomised into the study will be compared with those 
Figure 2 Study data flow diagram. NHS, National Health Service. 
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who received usual care to consider the clinical impact of 
any increase in attendance found. SPSS statistical package 
(V.25.0+) will be used to manage the quantitative analysis.
A per-protocol analysis will test whether the differ-
ence between groups is stronger among those who were 
exposed to the intervention (as far as we can tell, eg, 
letters sent and not ‘returned to sender’, PN received vs 
attempted).
Process evaluation
Survey responses will be analysed descriptively. If the 
number of completed surveys allows, analysis of variance 
will be used to explore if views regarding the interven-
tions and their impact differ between GP practices or 
staff groups (eg, GPs compared with healthcare assis-
tants). A qualitative content analysis will be applied to any 
open-ended responses within the survey and to interview 
transcripts with patients. The analysis will be led by one 
researcher with a proportion second coded and discussed 
with members of the research team. Member checking 
of transcripts is not appropriate or necessary for the 
purposes of this evaluation. A data management tool (eg, 
NVivo or Quirkos) will be used to support analysis.
Economic analysis
At the end of the study, we will conduct an economic 
analysis to explore the potential of reducing treatment 
costs and increasing the quality-adjusted life years of the 
population through the reduced incidence and mortality 
of CRC. Pre-existing data on lifetime costs and benefits 
will be used in the analysis.
Patient and public involvement
This study benefits from having three patient and public 
representatives either in the core team (author MG) or 
in our advisory committee. All have been involved in the 
preparation of this study and have provided feedback on 
study design and/or intervention and notification mate-
rials. Public survey interviews to consider the proposed 
interventions were conducted initially, followed by code-
sign workshops with members of the local community to 
refine the content and format of the intervention mate-
rials. Our patient and public representatives will also 
have a role to play in the PN training process. As the 
study progresses our patient and public representatives 
will continue to be consulted and opportunities to be 
involved in dissemination of the results put forward.
EthICs And dIssEMInAtIon
All relevant approvals have been obtained (eg, Health 
Research Authority). The online mailing company has all 
the appropriate security measures in place (ie, ISO27001 
certificate and NHS IG Toolkit) and a data processing 
agreement has been confirmed. The study protocol has 
been written in line with the Standard Protocol Items: 
Recommendations for Interventional Trials statement.19 20 
Any protocol amendments will be confirmed through the 
appropriate channels, the research team informed of the 
outcome and trial registration updated accordingly.
The results of the trial will be written up by the research 
team and published in peer-reviewed journals, presented 
at relevant conferences and reported on the website of 
the researchers and funders. A summary of the results will 
also be made available for each participating GP practice 
to disseminate to staff and patients.
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